Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by ASB Consultores LLC

ASB Consultores LLC lessened its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 8.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,700 shares of the company’s stock after selling 1,600 shares during the period. ASB Consultores LLC’s holdings in Elanco Animal Health were worth $255,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new position in Elanco Animal Health during the 4th quarter worth $62,510,000. Canada Pension Plan Investment Board bought a new position in Elanco Animal Health in the 2nd quarter valued at about $55,599,000. Primecap Management Co. CA increased its stake in Elanco Animal Health by 2.9% during the 4th quarter. Primecap Management Co. CA now owns 50,600,324 shares of the company’s stock valued at $753,945,000 after buying an additional 1,431,665 shares during the period. Wolf Hill Capital Management LP bought a new stake in shares of Elanco Animal Health during the 4th quarter worth about $20,683,000. Finally, Great Lakes Advisors LLC bought a new stake in shares of Elanco Animal Health during the 2nd quarter worth about $16,043,000. 97.48% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a research note on Thursday. Piper Sandler lowered their price target on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Monday, July 1st. Morgan Stanley downgraded Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $17.00 to $15.00 in a research note on Thursday. Finally, Barclays decreased their target price on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, June 28th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Elanco Animal Health presently has an average rating of “Hold” and a consensus price target of $17.29.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN opened at $14.07 on Friday. The company has a market capitalization of $6.95 billion, a PE ratio of -5.31, a price-to-earnings-growth ratio of 1.44 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.75 and a current ratio of 2.93. The stock has a fifty day moving average of $13.95 and a 200-day moving average of $15.16. Elanco Animal Health Incorporated has a one year low of $8.52 and a one year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. The business had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. Elanco Animal Health’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter last year, the company posted $0.18 EPS. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Activity

In other news, Director Michael J. Harrington acquired 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was purchased at an average price of $14.85 per share, with a total value of $51,975.00. Following the purchase, the director now owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 100,000 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were bought at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the acquisition, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at $1,886,450. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael J. Harrington purchased 3,500 shares of Elanco Animal Health stock in a transaction dated Thursday, August 22nd. The stock was bought at an average cost of $14.85 per share, with a total value of $51,975.00. Following the completion of the transaction, the director now directly owns 81,094 shares of the company’s stock, valued at $1,204,245.90. The disclosure for this purchase can be found here. 0.57% of the stock is owned by company insiders.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.